Myriad Genetics, Inc. announced that its MyRisk® Hereditary Cancer Test with RiskScore® was recognized in the American Journal of Human Genetics as one of the top 10 significant advances in ...
Hosted on MSN1mon
MYGN Stock Might Gain From the New Recognition of RiskScore StudyMyriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human ...
Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...
which features the MyRisk with RiskScore Hereditary Cancer test. The latest collaboration with Storm will bolster the company’s Hereditary Cancer testing business. Myriad Genetic’s shares ...
Myriad’s Breast Cancer Risk Assessment Program features the MyRisk ® with RiskScore ® Hereditary Cancer Test, the first and industry-leading hereditary cancer test and polygenic breast cancer risk ...
Storm will promote the MyRisk® with RiskScore® Hereditary Cancer Test, which evaluates genetic risks for various cancers. She emphasizes the significance of understanding family health history ...
SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk ® Hereditary Cancer ...
Morningstar brands and products Company Portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback